Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Top Cited Papers
- 17 February 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (5), 2534-2575
- https://doi.org/10.1021/acs.jmedchem.0c01845
Abstract
The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody–drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD4 levels. These experiments culminate with the identification of one degrader conjugate, which exhibits antigen-dependent antiproliferation effects in LNCaP prostate cancer cells.Keywords
This publication has 96 references indexed in Scilit:
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerNature, 2014
- Targeting bromodomains: epigenetic readers of lysine acetylationNature Reviews Drug Discovery, 2014
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie-International Edition, 2014
- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation TechnologyBioconjugate Chemistry, 2013
- Rapid Measurement of Intracellular Unbound Drug ConcentrationsMolecular Pharmaceutics, 2013
- Selective inhibition of BET bromodomainsNature, 2010
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004
- Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transportInternational Journal of Pharmaceutics, 1998
- N-benzyloxycarbonylaziridine in the syntheses of 2-aminoethyl armed lariats and selectively N-protected polyazacrown ethersJournal of the Chemical Society, Perkin Transactions 1, 1993
- THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULEProceedings of the National Academy of Sciences, 1969